ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1391

Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study

Patryk Drobinski1, Anne Bay-Jensen 2, Morten Karsdal 3 and Anne Siebuhr 4, 1University of Copenhagen/Nordic Bioscience, Copenhagen, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Copenhagen, Denmark, 4Nordic Bioscience, Herlev

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Response to treatments in Rheumatoid Arthritis (RA) is assessed by symptomatic changes, such as ACR-response and DAS28. However, such assessments do not provide information about the effect of the treatment at tissue level. Chronic inflammation is a harmful mechanism, which manifests in upregulated tissue remodeling and release of extracellular matrix (ECM) metabolites into circulation. Released ECM metabolites are biomarkers of tissue remodeling and give insight to treatment effect at tissue level. The purpose of this study was to investigate if tissue remodeling is modulated by tocilizumab (TCZ) and methotrexate (MTX) in the AMBITION study.

Methods: The AMBITION study is a phase III RCT in which TCZ monotherapy (8 mg/kg every 4 weeks) was compared to MTX monotherapy (starting at 7.5 mg/kg and titrated to 20 mg/kg) over 24 weeks in patients with early RA. Tissue metabolites were measured in baseline and 8-weeks sera from 387 patients by validated ELISA assays. Connective tissue remodeling was measured by C1M and C3M (type I and III collagen degradation), cartilage degradation by C2M (type II collagen degradation), basement membrane remodeling by C4M (type IV collagen degradation), systemic inflammation by C-reactive protein (CRP) and tissue specific inflammation by CRPM (an MMP-derived CRP metabolite). Comparison between treatment and response groups were done by ANCOVA, Spearman’s correlation and Logistic regression adjusted for age, gender, BMI and disease duration.

Results: Connective tissue remodeling biomarkers, C1M and C3M, were significantly (P< 0.05) inhibited by TCZ and C3M by MTX (P=0.0072) compared to placebo (see table 1). The inhibition of C1M and C3M with TCZ was respectively 24% and 16% greater than that of MTX (P=0.004 and P=0.0001). C4M was likewise inhibited by both TCZ and MTX, but the effect of TCZ was 22% greater than MTX (P< 0.0001). In contrast, TCZ and MTX had minimal effect on C2M when compared to placebo or baseline. MTX had no effect on CRP and CRPM compared to placebo or baseline, whereas TCZ reduced the level of CRP and CRPM to 31% and 73% of baseline. In the patients treated with TCZ none of the tested biomarkers correlated to 8 and 16-week changes in DAS28. In the MTX group changes in C4M and CRPM were correlated to 8-week changes in DAS28 (rho=0.21 and 0.19, P< 0.05), whereas only C4M correlated to 16-week changes in DAS28 (rho=0.19, P< 0.05). Patients with ACR70 response at week 8 had the highest difference between treatments in the inhibition of C1M; 36% for TCZ and 14% for MTX.

Conclusion: This study shows that tissue remodeling in the RA patients can be differently modulated by Tocilizumab and Methotrexate. Both treatments downregulate tissue remodeling and slower the disease progression. Tocilizumab showed a more tissue-protective effect and greater improvement of the disease symptoms than that of Methotrexate.  

Table 1. ANCOVA comparison between treatment groups and measured biomarkers change to week 8.


Disclosure: P. Drobinski, None; A. Bay-Jensen, Nordic Bioscience, 1, 2, 3; M. Karsdal, Nordic Biosceince, 1, 3, Nordic Bioscience, 1, 2, 3, 4, 5; A. Siebuhr, Nordic Bioscience, 3.

To cite this abstract in AMA style:

Drobinski P, Bay-Jensen A, Karsdal M, Siebuhr A. Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/connective-tissue-remodeling-is-differently-modulated-by-tocilizumab-versus-methotrexate-monotherapy-in-patients-with-early-ra-the-ambition-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/connective-tissue-remodeling-is-differently-modulated-by-tocilizumab-versus-methotrexate-monotherapy-in-patients-with-early-ra-the-ambition-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology